HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

BCLXL gene therapy moderates neuropathology in the DBA/2J mouse model of inherited glaucoma.

Abstract
Axonal degeneration of retinal ganglion cells (RGCs) causes blindness in glaucoma. Currently, there are no therapies that target axons to prevent them from degenerating. Activation of the BAX protein has been shown to be the determining step in the intrinsic apoptotic pathway that causes RGCs to die in glaucoma. A putative role for BAX in axonal degeneration is less well elucidated. BCLXL (BCL2L1) is the primary antagonist of BAX in RGCs. We developed a mCherry-BCLXL fusion protein, which prevented BAX recruitment and activation to the mitochondria in tissue culture cells exposed to staurosporine. This fusion protein was then packaged into adeno-associated virus serotype 2, which was used to transduce RGCs after intravitreal injection and force its overexpression. Transduced RGCs express mCherry-BCLXL throughout their somas and axons along the entire optic tract. In a model of acute optic nerve crush, the transgene prevented the recruitment of a GFP-BAX fusion protein to mitochondria and provided long-term somal protection up to 12 weeks post injury. To test the efficacy in glaucoma, DBA/2J mice were transduced at 5 months of age, just prior to the time they begin to exhibit ocular hypertension. Gene therapy with mCherry-BCLXL did not affect the longitudinal history of intraocular pressure elevation compared to naive mice but did robustly attenuate both RGC soma pathology and axonal degeneration in the optic nerve at both 10.5 and 12 months of age. BCLXL gene therapy is a promising candidate for glaucoma therapy.
AuthorsRyan J Donahue, Rachel L Fehrman, Jenna R Gustafson, Robert W Nickells
JournalCell death & disease (Cell Death Dis) Vol. 12 Issue 8 Pg. 781 (08 10 2021) ISSN: 2041-4889 [Electronic] England
PMID34376637 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2021. The Author(s).
Chemical References
  • RNA, Messenger
  • bcl-X Protein
  • Green Fluorescent Proteins
Topics
  • Aging (pathology)
  • Animals
  • Dependovirus
  • Disease Models, Animal
  • Genetic Therapy
  • Glaucoma (complications, physiopathology, therapy)
  • Green Fluorescent Proteins (metabolism)
  • Intraocular Pressure
  • Mice, Inbred DBA
  • Mitochondria (metabolism)
  • Nerve Crush
  • Nerve Degeneration (complications, pathology)
  • Neurons (pathology)
  • Optic Nerve (metabolism, pathology)
  • Protein Transport
  • RNA, Messenger (genetics, metabolism)
  • Retinal Ganglion Cells (metabolism)
  • bcl-X Protein (genetics, therapeutic use)
  • Mice

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: